About the
Investigational Treatment

An investigational treatment is a medicine that has not yet been approved for use outside of clinical research studies. It is not yet known how safe it is or whether it works.
Learn more about the each of these conditions below.
The investigational treatment in these studies, telisotuzumab adizutecan (ABBV‑400 or Temab‑A), is a type of antibody-drug conjugate (ADC), which combines targeted therapy, which aims to target a specific protein on cells, and a payload to stop the DNA in cancer cells from replicating. It is being developed to target colorectal cancer, gastroesophageal adenocarcinoma, non-small cell lung cancer, and other solid tumors.
ADCs have 3 parts:
A monoclonal antibody (a lab-made antibody made to attach to a specific protein on cells) that targets tumor cells
A cell-killing part (the payload)
A linker that connects the payload to the antibody
This investigational treatment is designed to work differently than standard chemotherapy. It targets the protein, c-Met, which is found more commonly in solid tumor cells than in normal cells.
See If You Prequalify for a Cancer Study
The investigational treatment is under clinical development and is not approved for use in cancer by regulatory health authorities. Safety and effectiveness are under evaluation.

https://www.cancer.gov/types/lung/patient/non-small-cell-lung-treatment-pdq

Explore what you can do today.

See If You Prequalify for a Cancer Study
Many patients with metastatic CRC, GEA, or NSCLC with c-MET overexpression are seeking additional treatment options. Researchers are dedicated to opening up new possibilities through clinical research. Join them on this expedition and explore the AndroMETa Studies.
See If You’re Eligible
Colorectal cancer (CRC), gastroesophageal adenocarcinoma (collectively referred to here as GEA, which includes gastric, gastroesophageal junction, and esophageal adenocarcinomas), and non-small cell lung cancer (NSCLC) are all types of adenocarcinomas. An adenocarcinoma is a type of cancer that starts in the glands that line your organs.

CRC

CRC starts in the colon or rectum.

GEA

GEA can start in the stomach, the esophagus, or where the two organs meet—the junction.

NSCLC

NSCLC starts in the lung's tissue